Erdong Zhang
Erdong Zhang has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Zhiyong Hou
Department of Orthopedic Surgery, Hebei Medical University Third Hospital
2 shared publications Feng Luan
Department of Otolaryngology The Third Hospital of Hebei Medical University Shijiazhuang People's Republic of China
1 shared publicationFengyu Liu
Orthopaedic Research Institute of Hebei Province Shijiazhuang People's Republic of China
1 shared publicationGuoqiang Li
Orthopaedic Research Institute of Hebei Province Shijiazhuang People's Republic of China
1 shared publicationHaofei Wang
Hebei Medical University Third Affiliated Hospital
1 shared publicationHaopei Li
The Second Hospital of Hebei Medical University
1 shared publication
Latest Publications
- Open Access
- 13 August 2026
- Published by Wiley in Immunology
- Vol. 179 (4) , 565-578
Emerging Roles of PSTPIP2 in Autoimmunity: From Mechanism to Therapeutic Implications
Autoimmune and autoinflammatory diseases are characterised by dysregulated immune activation and persistent inflammation, yet effective mechanism‐based therapeutic targets remain limited. Proline‐serine–threonine phosphatase‐interacting protein 2 (PSTPIP2), a membrane–cytoskeleton‐associated adaptor protein predominantly expressed in myeloid cells, has emerged as an important endogenous regulator of inflammatory responses. This review summarises the molecular structure, expression pattern and biological functions of PSTPIP2, with particular emphasis on its role in coordinating cytoskeletal remodelling, inflammatory signalling and immune‐cell behaviour. We further discuss the major mechanisms through which PSTPIP2 regulates disease progression, including suppression of IL‐1β maturation, inhibition of NF‐κB and ERK signalling, modulation of macrophage polarisation and control of osteoclast‐associated bone remodelling. In addition, recent advances in understanding the involvement of PSTPIP2 in chronic multifocal osteomyelitis, rheumatoid arthritis, SAPHO syndrome and bullous pemphigoid are reviewed, together with evidence from PSTPIP2 ‐deficient models that has provided important mechanistic and translational insights. Finally, the potential value of PSTPIP2 as a biomarker and therapeutic target is highlighted. Overall, PSTPIP2 represents a critical immunoregulatory node linking cytoskeletal organisation to inflammatory control, and further investigation of its molecular functions may facilitate the development of precision therapies for autoimmune and autoinflammatory diseases.
- 13 August 2026
- Published by Wiley in Immunology
- Vol. 179 (4) , 565-578
Open AccessEmerging Roles of PSTPIP2 in Autoimmunity: From Mechanism to Therapeutic Implications
Autoimmune and autoinflammatory diseases are characterised by dysregulated immune activation and persistent inflammation, yet effective mechanism‐based therapeutic targets remain limited. Proline‐serine–threonine phosphatase‐interacting protein 2 (PSTPIP2), a membrane–cytoskeleton‐associated adaptor protein predominantly expressed in myeloid cells, has emerged as an important endogenous regulator of inflammatory responses. This review summarises the molecular structure, expression pattern and biological functions of PSTPIP2, with particular emphasis on its role in coordinating cytoskeletal remodelling, inflammatory signalling and immune‐cell behaviour. We further discuss the major mechanisms through which PSTPIP2 regulates disease progression, including suppression of IL‐1β maturation, inhibition of NF‐κB and ERK signalling, modulation of macrophage polarisation and control of osteoclast‐associated bone remodelling. In addition, recent advances in understanding the involvement of PSTPIP2 in chronic multifocal osteomyelitis, rheumatoid arthritis, SAPHO syndrome and bullous pemphigoid are reviewed, together with evidence from PSTPIP2 ‐deficient models that has provided important mechanistic and translational insights. Finally, the potential value of PSTPIP2 as a biomarker and therapeutic target is highlighted. Overall, PSTPIP2 represents a critical immunoregulatory node linking cytoskeletal organisation to inflammatory control, and further investigation of its molecular functions may facilitate the development of precision therapies for autoimmune and autoinflammatory diseases.
- Open Access
- 21 January 2026
- Published by SAGE Publications in Clinical and Applied Thrombosis/Hemostasis
- Vol. 32
Study on Deep Vein Thrombosis Incidence and Risk Factors in Orthopedic Trauma Patients with Chronic Hepatitis B: 579 Cases Analyzed
Background: Chronic hepatitis B virus (HBV) infection remains highly prevalent worldwide, particularly in China. However, its influence on the risk of venous thromboembolism (VTE) following orthopedic trauma has not been well characterized. This study aimed to investigate the incidence and risk factors of deep vein thrombosis (DVT) in HBV-infected patients after lower extremity fractures. Methods: We retrospectively reviewed the medical records of adult patients with chronic HBV infection who were hospitalized for lower extremity fractures at a tertiary trauma center between December 2013 and January 2024. Demographic, clinical, and laboratory data were collected. DVT was diagnosed using bilateral lower extremity Doppler ultrasonography. Univariate and multivariate logistic regression analyses were performed to identify independent risk factors. Receiver operating characteristic (ROC) curve analysis was used to determine optimal cutoff values for continuous predictors. Results: Among 579 eligible patients, the overall incidence of post-fracture DVT was 30.4%. Independent risk factors identified in multivariate analysis included multiple fractures ( P < .001, OR = 4.009, 95% CI:2.080 ∼ 7.725), a history of cerebral infarction ( P = .009, OR = .753, 95% CI:1.287 ∼ 5.886), a history of cirrhosis ( P < .001, OR = 5.211, 95% CI:3.273 ∼ 8.297),and elevated HBsAg levels ( P < .001, OR = 1.002, 95% CI: 1.001 ∼1.003). Higher hemoglobin levels ( P < .001, OR = 0.979, 95% CI:0.970 ∼ 0.988) were independently associated with reduced DVT risk. In contrast, commonly used biomarkers such as D-dimer, fibrin degradation products (FDP), and liver function scores, including the Child–Pugh score and the Model for End-Stage Liver Disease (MELD) score, were not significant predictors in multivariate analysis. Conclusions: DVT is a common complication after lower extremity fractures in patients with chronic HBV infection. Multiple fractures, elevated HBsAg levels, prior stroke, and cirrhosis were independently associated with a higher risk of DVT, whereas higher hemoglobin levels were associated with a lower risk. These findings suggest that individualized thromboprophylaxis strategies may be considered in HBV-infected trauma patients.
- 21 January 2026
- Published by SAGE Publications in Clinical and Applied Thrombosis/Hemostasis
- Vol. 32
Open AccessStudy on Deep Vein Thrombosis Incidence and Risk Factors in Orthopedic Trauma Patients with Chronic Hepatitis B: 579 Cases Analyzed
Background: Chronic hepatitis B virus (HBV) infection remains highly prevalent worldwide, particularly in China. However, its influence on the risk of venous thromboembolism (VTE) following orthopedic trauma has not been well characterized. This study aimed to investigate the incidence and risk factors of deep vein thrombosis (DVT) in HBV-infected patients after lower extremity fractures. Methods: We retrospectively reviewed the medical records of adult patients with chronic HBV infection who were hospitalized for lower extremity fractures at a tertiary trauma center between December 2013 and January 2024. Demographic, clinical, and laboratory data were collected. DVT was diagnosed using bilateral lower extremity Doppler ultrasonography. Univariate and multivariate logistic regression analyses were performed to identify independent risk factors. Receiver operating characteristic (ROC) curve analysis was used to determine optimal cutoff values for continuous predictors. Results: Among 579 eligible patients, the overall incidence of post-fracture DVT was 30.4%. Independent risk factors identified in multivariate analysis included multiple fractures ( P < .001, OR = 4.009, 95% CI:2.080 ∼ 7.725), a history of cerebral infarction ( P = .009, OR = .753, 95% CI:1.287 ∼ 5.886), a history of cirrhosis ( P < .001, OR = 5.211, 95% CI:3.273 ∼ 8.297),and elevated HBsAg levels ( P < .001, OR = 1.002, 95% CI: 1.001 ∼1.003). Higher hemoglobin levels ( P < .001, OR = 0.979, 95% CI:0.970 ∼ 0.988) were independently associated with reduced DVT risk. In contrast, commonly used biomarkers such as D-dimer, fibrin degradation products (FDP), and liver function scores, including the Child–Pugh score and the Model for End-Stage Liver Disease (MELD) score, were not significant predictors in multivariate analysis. Conclusions: DVT is a common complication after lower extremity fractures in patients with chronic HBV infection. Multiple fractures, elevated HBsAg levels, prior stroke, and cirrhosis were independently associated with a higher risk of DVT, whereas higher hemoglobin levels were associated with a lower risk. These findings suggest that individualized thromboprophylaxis strategies may be considered in HBV-infected trauma patients.